CHICAGO & CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS CancerTM, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor & normal samples.

GPS CancerTM integrates targeted quantitative proteomics with whole genome (DNA) and whole transcriptome (RNA) sequencing, and a knowledge database containing hundreds of oncogenes and approximately 1,500 cellular pathways to identify genomic and proteomic alterations—from DNA to RNA to protein— targeting proteins with high clinical relevance to each person’s tumor and providing oncologists with a detailed molecular profile of a patient’s cancer to inform personalized treatment strategies.

With the capability to measure at a quantitative level, proteins which have known clinical significance relating to activity or resistance to chemotherapy, monoclonal antibody therapy (mAb), hormonal therapy, small molecule targeted therapy and checkpoint inhibitors, GPS CancerTM is the most comprehensive molecular profiling solution of a patient's tumor tissue. Combined with whole genome and transcriptomic analysis, this test provides informed clinical decision support, arming the physician with insight into the patient’s response and resistance to particular therapeutics before treatment begins. This valuable information is available within 21 days of receipt of the tissue, thus enabling clinical utility.

NantHealth will be exhibiting GPS CancerTM and its other solutions for cancer care at ASCO booth #12135 from June 3-June 7, 2016.

GPS CancerTM results are available to doctors in an easy-to-read report or accessible through the GPS CancerTM Genome Browser, a mobile application available on smartphones including the BlackBerry Priv. The GPS Cancer Genome Browser is the first app enabling a physician and molecular scientists to browse the patient's whole genome down to a single base pair and provide visual insight into genomic alterations coupled to relevant data about that alteration.

GPS CancerTM testing is conducted in the CLIA-certified and CAP-accredited laboratory of NantOmics, and is an enabler for the Cancer MoonShot 2020, the world’s most comprehensive cancer care collaborative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.

Products and Clearances Homepage